Joyce O'Shaughnessy, MD

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.

Joyce O’Shaughnessy, MD, discusses the findings from the phase 3 monarchE trial of adjuvant endocrine therapy with or without abemaciclib in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

A panel of breast oncologists highlight exciting treatment strategies being explored in clinical trials to help address treatment limitations in HR+/HER2- metastatic breast cancer.

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.